Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Sclerosteosis is an autosomal recessive sclerosing bone dysplasia characterized by progressive skeletal overgrowth. The majority of affected individuals have been reported in the Afrikaner population of South Africa, where a high incidence of the disorder occurs as a result of a founder effect. Homozygosity mapping in Afrikaner families along with analysis of historical recombinants localized sclerosteosis to an interval of approximately 2 cM between the loci D17S1787 and D17S930 on chromosome 17q12-q21. Here we report two independent mutations in a novel gene, termed "SOST." Affected Afrikaners carry a nonsense mutation near the amino terminus of the encoded protein, whereas an unrelated affected person of Senegalese origin carries a splicing mutation within the single intron of the gene. The SOST gene encodes a protein that shares similarity with a class of cystine knot-containing factors including dan, cerberus, gremlin, prdc, and caronte. The specific and progressive effect on bone formation observed in individuals affected with sclerosteosis, along with the data presented in this study, together suggest that the SOST gene encodes an important new regulator of bone homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in genes that have highly enriched expression in osteocytes cause rare bone and mineral disorders.”
From Osteocyte transcriptome mapping identifies a molecular landscape controlling skeletal homeostasis and susceptibility to skeletal disease (2021) · cites this paper as [17]
Citations
Cites
Bone: Formation by Autoinduction
Urist, M. R. (1965) · Science · doi:10.1126/science.150.3698.893 · Cited by 5,546 · cited 1×
“Although this family of morpho-gens was originally identified on the basis of bone-in-ducing activity (Urist 1965), a number of these factors have been shown to be critical for very early stages of embryogenesis and fetal development.”
Prediction of complete gene structures in human genomic DNA
Burge, C., & Karlin, S. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.0951 · Cited by 4,228 · cited 8×
“The novel variant gene (designated “P50gsc3”) predicted by GENSCAN was located between markers D17S951 and D17S1860 (fig.”
InfluentialA comprehensive genetic map of the human genome based on 5,264 microsatellites
Dib, C., Fauré, S., Fizames, C., Samson, D., Drouot, N., Vignal, A., Millasseau, P., Marc, S., Kazan, J., Seboun, E., et al. (1996) · Nature · doi:10.1038/380152a0 · Cited by 2,928 · cited 3×
“D17S1793, D17S1789, D17S951, and D17S1860 within the critical region bounded by D17S1787 and D17S930, an interval of ∼ 2 cM (Dib et al. 1996) on the cytogenetic border between the chromosomal bands 17q12–q21.”
Bone morphogenetic proteins: multifunctional regulators of vertebrate development.
Hogan, B. L. (1996) · Genes & Development · doi:10.1101/gad.10.13.1580 · Cited by 1,962
Therapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767 · cited 1×
“Currently there is no effective treatment for the restoration of normal bone mass in individuals with pathologically low skeletal density, and there is a large unmet need for therapy that can increase bone deposition in osteoporosis (Rodan and Martin 2000).”
BackgroundEasy calculations of lod scores and genetic risks on small computers.
Lathrop, M. G., & Lalouel, J.-M. (1984) · Europe PMC (PubMed Central) · Cited by 1,526
Faster sequential genetic linkage computations.
Cottingham, R. W., Idury, R. M., & Schäffer, A. A. (1993) · Europe PMC (PubMed Central) · Cited by 1,364
Nonsense-mediated mRNA decayin health and disease
Frischmeyer, P. A. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.10.1893 · Cited by 992 · cited 1×
“The relatively low levels of mutant transcripts observed could be the result of nonsense-mediated mRNA decay, as the inclusion of intronic sequence introduced an in-frame nonsense codon (Frischmeyer and Dietz 1999; Hentze and Kulozik 1999).”
BackgroundHomozygosity Mapping: A Way to Map Human Recessive Traits with the DNA of Inbred Children
Lander, E. S., & Botstein, D. (1987) · Science · doi:10.1126/science.2884728 · Cited by 875
FORMATION AND FUNCTION OF SPEMANN'S ORGANIZER
Harland, R., & Gerhart, J. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.611 · Cited by 839 · cited 1×
“In addition, the requirement for the coordinated expression of negative regulators of BMP activity, such as noggin and chordin, as well as members of the dan family, has been well described (Harland and Gerhart 1997; Sasai and De Robertis 1997; Hsu et al. 1998).”
Background
Research works printed but not linked: 3
- Gardner J (1999) Profound childhood deafness in South Africa: a clinical and molecular genetic approach. Ph.D. thesis, University of Cape Town, Cape Town
- Hausen, 1967, Sklerosteose, Vol. 6, 351
- Peitruschka, 1958, Weitere Mitteilungen über die Marmorknochenkrankheit (Albers-Schonbergsche Krankheit) nebst Bemerkungen zur Differentialdiagnose, Klin Monatbl, 132, 509
Cited by
Items 401–500 of 1,000
New insights into the location and form of sclerostin
Hernández, P., Whitty, C., Wardale, R. J., & HENSON, F. M. D. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.03.079 · Cited by 40
The osteocyte as a therapeutic target in the treatment of osteoporosis
Rochefort, G. Y. (2014) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x14523500 · Cited by 48
“The difference between these two disorders might be explained by the fact that the deleted genomic region in van Buchem disease includes no regulatory elements required for sclerostin expression during the embryologic steps of digit formation [Brunkow et al. 2001; Uitterlinden et al. 2004].”
BackgroundMolecular and radiological diagnosis of sclerosing bone dysplasias
Hul, W. V., Vanhoenacker, F. M. H. M., Balemans, W., Janssens, K., & de Schepper, A. M. (2001) · European Journal of Radiology · doi:10.1016/s0720-048x(01)00400-4 · Cited by 43
“Recently, the gene SOST encoding a protein with a currently unknown function, was identified and proven to cause sclerosteosis [38,39].”
BackgroundPiec, I., Washbourne, C. J., TANG, J. C. Y., Fisher, E., Greeves, J. P., Jackson, S., & Fraser, W. D. (2016) · Calcified Tissue International · doi:10.1007/s00223-015-0105-3 · Cited by 41
“Sclerostin was discovered as a product of the SOST gene causing sclerosteosis [1, 2], and van Buchem syndrome [3, 4], and later confirmed in mice in which the SOST gene had been deleted [5] or overexpressed [6].”
BackgroundLRP5, serotonin, and bone: Complexity, contradictions, and conundrums
Goltzman, D. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.462 · Cited by 41
Carbonic anhydrase III protects osteocytes from oxidative stress
Shi, C., Uda, Y., Dedic, C., Azab, E., Sun, N., Hussein, A. I., Petty, C. A., Fulzele, K. S., Mitterberger, M. C., Zwerschke, W., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201700485rr · Cited by 42
Impaired Bone Homeostasis in Amyotrophic Lateral Sclerosis Mice with Muscle Atrophy
Zhu, K., Yi, J., Xiao, Y., Lai, Y., Song, P., Zheng, W., Jiao, H., Fan, J., Wu, C., Chen, D., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.603985 · Cited by 38
“Osteocyte-derived sclerostin, which is encoded by the Sost gene (27), can be induced by mechanical unloading and inhibits Wnt/ -catenin signaling in osteoblasts (12, 28, 29).”
BackgroundJohnson, M. L., Picconi, J. L., & Recker, R. R. (2002) · The Endocrinologist · doi:10.1097/00019616-200209000-00012 · Cited by 37
Effects of low intensity vibration on bone and muscle in rats with spinal cord injury
Bramlett, H. M., Dietrich, W. D., Marcillo, A. E., Mawhinney, L. J., Furones-Alonso, O., Bregy, A., Peng, Y., Wu, Y., Pan, J., Wang, J., et al. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2748-8 · Cited by 40
Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis
Lewiecki, E. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.540565 · Cited by 39
“Although sclerostin/SOST appears to be predominately expressed in osteocytes [14], quantitative real time-PCR analyses have demonstrated a significant presence in cartilage, kidney and liver, with detectable lower levels in placenta and fetal skin [60].”
BackgroundFracture healing: From basic science to role of nutrition
Maria, G. G. (2014) · Frontiers in bioscience · doi:10.2741/4273 · Cited by 41
“The identification of sclerostin and the demonstration that its expression in the bony tissue is restricted primarily to the osteocytes, provided the first functional evidence that osteocytes directly control bone formation (40).”
BackgroundLipoprotein receptor–related protein 6 is required for parathyroid hormone–induced Sost suppression
Li, C., Wang, W., Xie, L., Luo, X., Cao, X., & Wan, M. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12750 · Cited by 40
Association of circulating sclerostin with vascular calcification in Afro-Caribbean men
Kuipers, A. L., Miljkovic, I., Carr, J. J., Terry, J. G., Nestlerode, C. S., Ge, Y., Bunker, C. H., Patrick, A. L., & Zmuda, J. M. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.010 · Cited by 37
Sclerostin and skeletal health
Sharifi, M., Ereifej, L. K., & Lewiecki, E. M. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-015-9311-6 · Cited by 38
“Sclerostin is a monomeric glycoprotein produced by the SOST gene primarily in osteocytes and in lesser amounts by cementocytes and mineralized chondrocytes [19, 20].”
BackgroundIncrease in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort
Nocturne, G., Pavy, S., Boudaoud, S., Séror, R., Goupille, P., Chanson, P., van der Heijde, D. M. F. M., van Gaalen, F. A., Berenbaum, F., Mariette, X., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134974 · Cited by 36
“In humans, mutation of SOST leads to van Buchem disease, characterized by hyperosteosis [15].”
BackgroundSignaling Pathways in Craniofacial Development
Neben, C. L., & Merrill, A. E. (2015) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2015.09.005 · Cited by 37
“…2 (614305) SOST, LRP4 type 1: Sclerosis of the skull, square mandible; type 2: frontal bossing, midface hypoplasia, enlarged sclerotic mandible, prognathism, malocclusion Brunkow et al. (2001) and Leupin et al. (2011) Tetra-amelia syndrome (273395) WNT3 Absent frontal bones, malformed mouth, and…”
BackgroundTime-dependent effects of sclerostin antibody on a mouse fracture healing model.
Cui, L., Cheng, H., Song, C., Li, C., Simonet, W. S., Ke, H. Z., & Li, G. (2013) · PubMed · Cited by 44
Shakeri, A., & Adanty, C. (2020) · Journal of Population Therapeutics & Clinical Pharmacology · doi:10.15586/jptcp.v27i1.655 · Cited by 35
Yavropoulou, M. P., Xygonakis, C., Lolou, M., Karadimou, F., & Yovos, J. G. (2014) · HORMONES · doi:10.14310/horm.2002.1552 · Cited by 42
Inducible Wnt16 inactivation: WNT16 regulates cortical bone thickness in adult mice
Ohlsson, C., Henning, P., Nilsson, K. H., Wu, J., Gustafsson, K. L., Sjögren, K., Törnqvist, A. E., Koskela, A., Zhang, F., Lagerquist, M. K., et al. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0020 · Cited by 35
SOST Inhibits Prostate Cancer Invasion
Hudson, B. D., Hum, N. R., Thomas, C. B., Kohlgruber, A. C., Sebastian, A., Collette, N. M., Coleman, M. A., Christiansen, B., & Loots, G. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142058 · Cited by 36
“For example, loss- and gain-of function mutations in LRP5 cause either low or high bone mass [6, 7] and inactivation of SOST causes two hyperosteoses disorders: sclerosteosis [8, 9] and van Buchem's disease [10, 11].”
BackgroundArdawi, M. S., Rouzi, A. A., & Qari, M. H. (2012) · Bone · doi:10.1016/j.bone.2012.02.092 · Cited by 35
Future directions for new medical entities in osteoporosis
Ferrari, S. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.08.002 · Cited by 34
Update on romosozumab: a humanized monoclonal antibody to sclerostin
Costa, A. G., Bilezikian, J. P., & Lewiecki, E. M. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.895808 · Cited by 37
“Sclerostin contains 190 amino-acid residues with a cysteine knot-like domain that is characteristic of the Cerebeus/DAN family of glycoproteins [16-18], which are antagonists of bone morphogenetic protein (BMP) signaling.”
BackgroundInfluentialBhattacharyya, S., Pal, S., & Chattopadhyay, N. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.02.028 · Cited by 34
Advances in Osteoimmunology: Pathophysiologic Concepts and Treatment Opportunities
Rauner, M., Sipos, W., Thiele, S., & Pietschmann, P. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000342426 · Cited by 35
Sclerostin: a possible target for the management of cancer-induced bone disease
Gkotzamanidou, M. A., Dimopoulos, M. A., Kastritis, E., Christoulas, D., Moulopoulos, L. A., & Terpos, E. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.697154 · Cited by 34
“Loss of expression of the SOST gene is the responsible genetic disorder causing sclerosteosis and van Buchem disease, two rare skeletal disorders associated with general progressive skeletal overgrowth and sclerosis of axial and appendicular skeleton [2,3].”
BackgroundKim, K. M., Lim, S. K., Moon, J. H., Jin, H., Jung, K. Y., Shin, C. S., Park, K. S., Jang, H. C., & Choi, S. H. (2015) · Bone · doi:10.1016/j.bone.2015.11.008 · Cited by 34
Romosozumab for the treatment of osteoporosis – a systematic review
Mäkinen, V.-N., Sølling, A. S., McClung, M. R., & Langdahl, B. L. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02469-1 · Cited by 36
“It was first recognized as a potential therapeutic target for osteoporosis following the identification of loss-of-function mutations in the SOST gene, the causative factor of sclerosteosis and van Buchem disease [1].”
InfluentialTalking among Ourselves: Paracrine Control of Bone Formation within the Osteoblast Lineage
Tonna, S. J., & Sims, N. A. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9738-2 · Cited by 40
“Sclerostin was first identified when loss of function mutations within its coding gene (SOST) were shown to associate with the high bone mass phenotype of Sclerosteosis [37].”
BackgroundYu, L., van der Valk, M., Cao, J., Han, C.-Y. E., Juan, T., Bass, M., Deshpande, C., Damore, M. A., Stanton, R., & Babij, P. (2011) · Bone · doi:10.1016/j.bone.2011.08.016 · Cited by 35
“Loss of function mutations in the sclerostin gene results in a high bonemass condition known as sclerosteosis [3,4] whereas a 52 kb deletion downstream of the gene leads to van Buchem's disease also associated with high bone mass [5,6].”
BackgroundThe Lrp4R1170Q Homozygous Knock-In Mouse Recapitulates the Bone Phenotype of Sclerosteosis in Humans
Boudin, E., Yorgan, T. A., Fijałkowski, I., Sonntag, S., Steenackers, E., Hendrickx, G., Peeters, S., Maré, A. D., Vervaet, B. A., Verhulst, A., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3160 · Cited by 33
Holdsworth, G., Staley, J. R., Hall, P., van Koeverden, I. D., Vangjeli, C., Okoye, R., Boyce, R. W., Turk, J. R., Armstrong, M., Wolfreys, A., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4287 · Cited by 33
Frysz, M., Gergei, I., Scharnagl, H., Smith, G. D., Zheng, J., Lawlor, D. A., Herrmann, M., März, W., & Tobias, J. H. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4467 · Cited by 35
“Sclerostin was originally identified from studies of the high bone mass disorder sclerosteosis, caused by loss-of-function mutations in the SOST gene encoding sclerostin.((2)) Anti-sclerostin antibody treatment has since been developed as a new treatment for osteoporosis acting by stimulating bone formation.”
BackgroundLin, C., Lin, R., Chang, C., Wang, G., & Lai, K. (2015) · Bioelectromagnetics · doi:10.1002/bem.21933 · Cited by 33
“Loss of function or deletion of the Sost gene leads to progressive bone overgrowths of these two diseases [Balemans et al., 1999, 2001; Brunkow et al., 2001].”
BackgroundNovel targets in bone and cartilage
Beyer, C., & Schett, G. A. (2010) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2010.03.001 · Cited by 35
Collins, J. N., Kirby, B. J., Woodrow, J. P., Gagel, R. F., Rosen, C. J., Sims, N. A., & Kovács, C. S. (2013) · Endocrinology · doi:10.1210/en.2012-1931 · Cited by 34
“Their physiological importance has been confirmed by loss-offunction mutations in Sost, which cause high bone mass in humans (58, 59), whereas ablation of Sost or heterozygous deletion of Dkk1 causes high bone mass in mice (57, 60–62).”
BackgroundIdentification of a DNA aptamer that inhibits sclerostin's antagonistic effect on Wnt signalling
Shum, K. T., Chan, C., Leung, C.-M., & Tanner, J. A. (2011) · Biochemical Journal · doi:10.1042/bj20101096 · Cited by 35
“Loss of function mutations in the gene coding for sclerostin, SOST, result in the congenital disease sclerosteosis, characterised by strong and dense bone [1-4].”
BackgroundZhu, L., Su, G., Dai, J. M., Zhang, W., Yin, C., Zhang, F.-Y., Zhu, Z., Guo, Z., Fang, J., Zou, C., et al. (2018) · Genomics · doi:10.1016/j.ygeno.2018.02.006 · Cited by 32
The Role of Angiogenetic Factors in Preeclampsia
Papapanagiotou, A., Daskalaki, M. A., Gargalionis, A. N., Margoni, A., Domali, E., Daskalakis, G., & Papavassiliou, A. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110431 · Cited by 36
Rapid phenotyping of knockout mice to identify genetic determinants of bone strength
Freudenthal, B., Logan, J. G., _, _., Croucher, P. I., Williams, G. R., & Bassett, J. H. D. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0258 · Cited by 34
Genetic approaches to metabolic bone diseases
Hannan, F. M., Newey, P. J., Whyte, M. P., & Thakker, R. V. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13803 · Cited by 34
Movérare‐Skrtic, S., Nilsson, K. H., Henning, P., Funck‐Brentano, T., Nethander, M., Rivadeneira, F., Nunes, G. C., Koskela, A., Tuukkanen, J., Tuckermann, J. P., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201900707r · Cited by 32
Sclerostin expression in trabecular bone is downregulated by osteoclasts
Koide, M., Yamashita, T., Murakami, K., Uehara, S., Nakamura, K., Nakamura, M., Matsushita, M., Ara, T., Yasuda, H., Penninger, J. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-70817-1 · Cited by 33
The Genetic Architecture of High Bone Mass
Gregson, C. L., & Duncan, E. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.595653 · Cited by 35
Sclerostin is a promising therapeutic target for oral inflammation and regenerative dentistry
Liao, C., Liang, S., Wang, Y., Zhong, T., & Liu, X. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03417-4 · Cited by 33
“Sclerostin: a molecule that regulates bone metabolism The SOST gene is located in the human chromosomal region 17q12-q21, with only two exons and one intron [8, 9].”
BackgroundKim, C. A., Honjo, R. S., Bertola, D. R., Albano, L. M. J., de Oliveira, L. R., Jales, S. M. D. C. P., Siqueira, J., Castilho, A. M., Balemans, W., Piters, E., et al. (2008) · Genetic Testing · doi:10.1089/gte.2008.0036 · Cited by 32
“Molecular genetic studies showed that sclerosteosis and van Buchem disease are allelic conditions caused by different mutations that all result in loss of function of the SOST gene (Balemans et al ., 2001, 2002, 2005; Brunkow et al ., 2001; Staehling-Hampton et al ., 2002).”
Boschert, V., van Dinther, M., Weidauer, S. E., van Pee, K., Muth, E.-M., ten Dijke, P., & Mueller, T. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081710 · Cited by 34
“Here gene expression of SOST (encoding Sclerostin) is either lost or blunted indicating that Sclerostin is a negative regulator of bone formation and its inhibition might restore normal bone formation rate [14,15].”
BackgroundOsteocyte-mediated mechanical response controls osteoblast differentiation and function
Buck, H., & Stains, J. P. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1364694 · Cited by 35
Novel approaches to the treatment of osteoporosis
Appelman‐Dijkstra, N. M., & Papapoulos, S. E. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.07.003 · Cited by 35
Glucocorticoids are not always deleterious for bone
van Lierop, A. H., Hamdy, N. A. T., & Papapoulos, S. E. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.151 · Cited by 31
“(2) Van Buchem disease is thought to have milder clinical manifestations than sclerosteosis, a craniotubular hyperostosis with similar phenotype due to inactivating mutations of the SOST gene.(6,7) Management of the complications of both these sclerosing dysplasias is surgical, aiming at removal of the excess of bone,…”
BackgroundCharacterization of a novel murine Sost ERT2 Cre model targeting osteocytes
Maurel, D. B., Matsumoto, T., Vallejo, J. A., Johnson, M. L., Dallas, S. L., Kitase, Y., Brotto, M. A. P., Wacker, M., Harris, M. A., Harris, S. E., et al. (2019) · Bone Research · doi:10.1038/s41413-018-0037-4 · Cited by 32
Rare versus common diseases: a false dichotomy in precision medicine
Chung, B. H., Chau, J. F. T., & Wong, G. K. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00176-x · Cited by 37
Wnt Pathway Extracellular Components and Their Essential Roles in Bone Homeostasis
Martínez‐Gil, N., Ugartondo, N., Grinberg, D., & Balcells, S. (2022) · Genes · doi:10.3390/genes13010138 · Cited by 37
Bone Lining Cells: Normal Physiology and Role in Response to Anabolic Osteoporosis Treatments
Wein, M. N. (2017) · Current Molecular Biology Reports · doi:10.1007/s40610-017-0062-x · Cited by 36
Determinants of Low Bone Turnover in Type 2 Diabetes-the Role of PTH
Vavanikunnel, J., Sewing, L., Triantafyllidou, M., Steighardt, A., Baumann, S., Egger, A., Grize, L., Felix, B., KRAENZLIN, M. E., Henzen, C., et al. (2022) · Calcified Tissue International · doi:10.1007/s00223-022-01022-7 · Cited by 31
“Amongst other mechanisms iPTH is supposed to downregulate the SOST gene encoding for sclerostin which is an osteocyte-specific secreted WNT-inhibitor of bone formation [28, 38, 39].”
BackgroundBaker, E. K., Taylor, S., Gupte, A., Chalk, A. M., Bhattacharya, S., Green, A. C., Martin, T. J., Strbenac, D., Robinson, M. D., Purton, L. E., et al. (2015) · Bone · doi:10.1016/j.bone.2014.12.063 · Cited by 30
“Of note, humans with sclerosteosis or the related van Buchem disease, both of which result frommutations reducing SOST expression or function, do not appear to be at increased risk of developing OS [17–22].”
BackgroundAgholme, F., Isaksson, H., Li, X., Ke, H. Z., & Aspenberg, P. (2011) · Acta Orthopaedica · doi:10.3109/17453674.2011.625539 · Cited by 29
“Sclerostin is an important negative regulator of bone, and naturally occurring mutations of the SOST gene in humans lead to the high bone mass condition sclerostosis (Balemans et al. 2001, Brunkow et al. 2001).”
Regulation of sclerostin by the SIRT1 stabilization pathway in osteocytes
Kim, J., Yang, Y.-S., Xie, J., Lee, O., Kim, J., Hong, J., Boldyreff, B., Filhol, O., Chun, H., Greenblatt, M. B., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00952-x · Cited by 32
Effects of Sclerostin Antibody on the Healing of Femoral Fractures in Ovariectomised Rats
Liu, Y., Rui, Y., Cheng, T.-Y., Huang, S., Xu, L., Meng, F., Lee, W., Zhang, T., Li, N., Li, C., et al. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-0085-3 · Cited by 29
Boudin, E., & Hul, W. V. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.06.003 · Cited by 32
Frizzled‐4 is required for normal bone acquisition despite compensation by Frizzled‐8
Kushwaha, P., Kim, S., Foxa, G. E., Michalski, M. N., Williams, B. O., Tomlinson, R. E., & Riddle, R. C. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29563 · Cited by 34
“…mass found in patients with sclerosteosis and van Buchem disease, owing to alterations in the SOST gene that encodes sclerostin (Balemans et al., 2001; Balemans et al., 2002; Brunkow et al., 2001), a secreted inhibitor of Wnt/β‐catenin signaling (Li et al., 2005; Semenov, Tamai, & He, 2005).”
Insights Into the Mechanisms of Sclerostin Action in Regulating Bone Mass Accrual
Williams, B. O. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2154 · Cited by 30
“The potential role(s) of other Sost‐interacting proteins such as Lrp4, components of the BMP signaling pathway,((10,13,35,36)) or others((37)) to modulate specific aspects of skeletal development and homeostasis and/or the interaction of Sost and Lrp5 or Lrp6 will require further investigation.”
BackgroundMabey, T., Honsawek, S., Tanavalee, A., Wilairatana, V., Yuktanandana, P., Saetan, N., & Zhan, D. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.03.011 · Cited by 30
“Inactivating mutations in the SOST gene can cause sclerosteosis and van Buchem disease which are bone dysplasia disorders characterized by progressive skeletal overgrowth [7–9].”
BackgroundToulis, K. A., Anastasilakis, A. D., Pοlyzos, S. A., & Makras, P. (2011) · HORMONES · doi:10.14310/horm.2002.1308 · Cited by 30
Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse
Sun, W., Shi, Y., Lee, W., Lee, S.-Y., & Long, F. (2016) · Bone · doi:10.1016/j.bone.2016.01.013 · Cited by 28
“Sclerostin deficiency in humans causes high bone mass syndromes such as sclerosteosis [20] and Van Buchem disease [21].”
Sclerostin measurement in human disease: Validity and current limitations
Costa, A. G., Cremers, S., & Bilezikian, J. P. (2016) · Bone · doi:10.1016/j.bone.2016.10.012 · Cited by 29
Macaulay, T. R., Siamwala, J. H., Hargens, A. R., & Macias, B. R. (2017) · Bone Reports · doi:10.1016/j.bonr.2017.08.004 · Cited by 28
“This primer pair has previously been validated (Brunkow et al., 2001).”
MethodMusculoskeletal Health in the Context of Spinal Cord Injury
Clark, J., & Findlay, D. M. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0400-1 · Cited by 28
Shan, Y., Wang, L., Li, G., Shen, G., Zhang, P., & Xu, Y. (2018) · Biochemistry and Cell Biology · doi:10.1139/bcb-2018-0170 · Cited by 28
“…and Cell Biology Draft 40 41 42 43 Introduction 44 Sclerostin (SOST) is a glycoprotein predominantly secreted by bone tissue 45 osteocytes, and is encoded by SOST in humans and other vertebrates (BALEMANS et al. 46 2001; BRUNKOW et al. 2001).”
BackgroundSaedi, A. A., Stupka, N., & Duque, G. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_358 · Cited by 32
Romosozumab — Promising or Practice Changing?
Rosen, C. J. (2017) · New England Journal of Medicine · doi:10.1056/nejme1711298 · Cited by 28
Peng, J., Zhang, D., Zhang, H., Aifei, W., Lianfu, D., & Xu, Y. (2021) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-021-04365-8 · Cited by 29
The effect of osteoporosis treatment on bone mass
Appelman‐Dijkstra, N. M., Oei, H. L. D. W., Veldhuis‐Vlug, A. G., & Winter, E. M. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101623 · Cited by 30
Positive and Negative Regulators of Sclerostin Expression
Iwamoto, R., Koide, M., Udagawa, N., & Kobayashi, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094895 · Cited by 31
Advancing our understanding of osteocyte cell biology
Guo, D., & Bonewald, L. F. (2009) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x09341484 · Cited by 30
“Research on sclerosteosis and van Buchem disease revealed mutations of a new gene named Sost responsible for the defects in these diseases [Balemans et al. 2001; Brunkow et al. 2001].”
BackgroundBarbe, M. F., Massicotte, V. S., Assari, S., Monroy, M. A., Frara, N. A., Harris, M. Y., Amin, M., King, T. E., Cruz, G. E., & Popoff, S. N. (2018) · Bone · doi:10.1016/j.bone.2018.02.014 · Cited by 28
Kashii, M., Matuso, Y., Sugiura, T., Fujimori, T., Nagamoto, Y., Makino, T., Kaito, T., Ebina, K., Iwasaki, M., & Yoshikawa, H. (2015) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-015-0671-5 · Cited by 27
“In 2001 the SOST gene, which encodes sclerostin, was identified as the gene responsible for sclerosteosis [15, 16].”
BackgroundRole of Regulators of G Protein Signaling Proteins in Bone Physiology and Pathophysiology
Jules, J., Yang, S., Chen, W., & Li, Y. (2015) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2015.02.002 · Cited by 29
“Other mutations have shown to affect the Wnt signaling by targeting sclerostin.(121,122) Indeed, sclerostin deficiency can cause sclerosteosis and Van Buchen disease, two autosomal recessive disor-”
BackgroundPathophysiology of Osteoporosis
Rodan, G. A., Raisz, L. G., & Bilezikian, J. P. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50175-x · Cited by 36
Sclerostin and Cardiovascular Disease
Tobias, J. H. (2023) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00810-w · Cited by 28
Diegel, C. R., Krämer, I., Moes, C., Foxa, G. E., McDonald, M. J., Madaj, Z., Guth, S., Liu, J., Harris, J. L., Kneissel, M., et al. (2023) · Bone Research · doi:10.1038/s41413-023-00278-5 · Cited by 29
“4,18,19,36,37 Subsequent work showed that subjects either completely lacking SOST expression (sclerosteosis 6,38 ) or having severely diminished SOST expression due to loss of a regulatory enhancer sequence that acted on the SOST promoter (van Buchem disease 39 ) also developed extremely high bone…”
BackgroundRelative influence of heritability, environment and genetics on serum sclerostin
Kuipers, A. L., Zhang, Y., Yu, S., Kammerer, C. M., Nestlerode, C. S., Chu, Y., Bunker, C. H., Patrick, A. L., Wheeler, V. W., Miljkovic, I., et al. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2517-0 · Cited by 26
“Although widely thought to be an osteocyte-specific protein [4], there is evidence that the SOST mRNA is expressed by other cells including articular chondrocytes, cementocytes [5, 6], and cells of the liver, blood vessels and kidneys [7].”
Jia, H., Ma, J. X., L., X., Yu, J. T., Feng, R., Xu, L. Y., Wang, J., Xing, D., Zhu, S., & Wang, Y. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2818-y · Cited by 28
Anabolic Strategies to Augment Bone Fracture Healing
Roberts, S. J., & Ke, H. Z. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0440-1 · Cited by 28
Emerging pharmacologic therapies for osteoporosis
Grey, A. B. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.3.493 · Cited by 27
“Thus, deletion of the gene encoding sclerostin is associated with increased bone mass [124,125] and forced overexpression of sclerostin causes osteoporosis [123] .”
BackgroundPhysiopathology of Osteoporosis: Nursing Involvement and Management
Valenzuela-Martínez, S., Ramírez-Expósito, M. J., Carrera-González, M. P., & Martínez-Martos, J. M. (2023) · Biomedicines · doi:10.3390/biomedicines11041220 · Cited by 32
McCann, M. R., Yeung, C., Pest, M. A., Ratneswaran, A., Pollmann, S. I., Holdsworth, D. W., Beier, F., Dixon, S. J., & Séguin, C. A. (2016) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2016.11.001 · Cited by 26
PCAN: phenotype consensus analysis to support disease-gene association
Godard, P., & Page, M. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1401-2 · Cited by 25
“Therefore, a holistic view of existing Mendelian disease genes will not only aid the discovery of novel disorders and associated genes but together resolve fundamental molecular mechanisms that give rise to human phenotypic traits of broad therapeutic potential [2, 3].”
BackgroundZou, J., Zhang, W., & Li, X. (2017) · Calcified Tissue International · doi:10.1007/s00223-016-0231-6 · Cited by 28
Romosozumab — on track or derailed?
Khosla, S. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.136 · Cited by 25
Ye, W., Wang, Y., Mei, B., Hou, S., Liu, X., Wu, G., Qin, L., Zhao, K., & Huang, Q. (2018) · Bone · doi:10.1016/j.bone.2018.01.001 · Cited by 25
Al-Qattan, M. M., & Alkuraya, F. S. (2018) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.60694 · Cited by 28
“Noncoding deletions that remove a SOST-specific regulatory element cause Van Buchem disease type 1 (OMIM 239100; increased cortical bone density with bony enlargement of the skull, mandible, ribs and the tubular bones of the hands and feet; Balemans et al., 2002; Brunkow et al., 2001).”
BackgroundSclerostin binds and regulates the activity of cysteine-rich protein 61
Craig, T. A., Bhattacharya, R., Mukhopadhyay, D., & Kumar, R. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.143 · Cited by 25
Liu, X., Li, C., Liu, K., Cai-yan, C., Zhang, Y., & Liu, Y. (2012) · Biological Trace Element Research · doi:10.1007/s12011-012-9333-9 · Cited by 27
Novel SOST gene mutation in a sclerosteosis patient and her parents
Bhadada, S. K., Rastogi, A., Steenackers, E., Boudin, E., Arya, A. K., Dhiman, V., Bhansali, A., & Hul, W. V. (2012) · Bone · doi:10.1016/j.bone.2012.10.009 · Cited by 25
“Previously, six different mutations have been identified in the SOST gene underlying sclerosteosis from different geographical regions, which include one missense [13], two splice site [9,11], and three nonsense mutations [9,10,12] (Table 1) (Fig.”
BackgroundRudmann, D. G., Page, T. J., Vahle, J. L., Chouinard, L., Hailé, S., Poitout, F. M., Baskin, G. B., Lambert, A.-J., Walker, P., Glazier, G., et al. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr318 · Cited by 25
Genetic Polymorphism in Extracellular Regulators of Wnt Signaling Pathway
Sharma, G., Sharma, A. R., Seo, E.-M., & Nam, J. (2015) · BioMed Research International · doi:10.1155/2015/847529 · Cited by 28
“It has been earlier reported that loss of function mutations in the SOST gene leads to monogenic bone disorder, sclerosteosis (Online Mendelian Inheritance inMan ID: 269500), characterized by hyperostosis all over the skeleton (massive bone overgrowth) [25, 26].”
BackgroundMéreuze, S., Vaché, C., Molinari, N., Vaudaine, J., Claustres, M., Roux, A., & Tuffery‐Giraud, S. (2009) · Human Mutation · doi:10.1002/humu.21070 · Cited by 24
Role of sclerostin in the pathogenesis of chronic kidney disease-mineral bone disorder
Asamiya, Y., Tsuchiya, K., & Nitta, K. (2016) · Renal Replacement Therapy · doi:10.1186/s41100-016-0024-4 · Cited by 24
“Additional studies are needed to determine Osteoid New bone Old bone HSC Bone marrow MSC Wnt Wnt Wnt Wnt Wnt SOST SOST Dkk 1 Dkk 1 RANK Monocyte RANKL RANKL OPG Osteoblast Osteocyte Mature osteoblast Lining cell Apoptosis Matrix mineralization ?”
Background
Metadata
- Authors
- Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., Alisch, R. S., Gillett, L., Colbert, T., Tacconi, P., Galas, D., Hamersma, H., Beighton, P., & Mulligan, J. T.
- Affiliations
- University of Cape Town (ZA)
- University of Cagliari (IT)
- Corresponding author
- Brunkow, Mary E.
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2001-03
- Volume
- 68
- Issue
- 3
- Pages
- 577-589
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1274471
- OpenAlex
- W2037750372
- Cited by
- 1,011
- References
- 50
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 32 · 2023: 27 · 2022: 36 · 2021: 53 · 2020: 52 · 2019: 46 · 2018: 50 · 2017: 56 · 2016: 65 · 2015: 61 · 2014: 58 · 2013: 60 · 2012: 56
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4523 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Dermatological and Skeletal Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Keywords
- sclerosteosis, SOST gene, skeletal dysplasia, cystine knot proteins, bone homeostasis, skeletal overgrowth, nonsense mutation, splicing mutation, founder effect, Afrikaner population, bone formation regulation
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Bone Diseases, Chromosome Mapping, Chromosomes, Human, Pair 17, Consanguinity, Cystine, Female, Genetic Markers, Homozygote, Humans, Male, Molecular Sequence Data, Netherlands, Pedigree, Proteins, Recombination, Genetic, Sclerosis, Senegal, South Africa, Conserved Sequence, Alternative Splicing, Bone Morphogenetic Proteins, Mutation, Missense, Black People, White People, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.